Transgene (TNG)

Business description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

TG4010 data met expectations

Update | Pharmaceutical & healthcare | 13/10/2014

Data from the Phase II stage of the TIME trial presented at the ESMO conference confirm the potential of TG4010 in non-small cell lung cancer (NSCLC). Discussions with regulators are ongoing, which should result in the Phase III stage of the trial starting in Q115. We also remain optimistic that Transgene will find a new partner for TG4010, because of the survival benefit observed so far and the prospect of an even greater benefit if combined with one of the promising immunotherapies (eg nivolumab) in development for NSCLC. We increase our valuation by €20m to €415m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€192.7m
Last close€3.105
High / Low (52 weeks)€3.6 / €2.5
Stock market listingEU
Forecast net debt (€m)29.4
Forecast gearing ratio (%)164
SectorPharmaceutical & healthcare

Price performance

Relative *(0.7)21.311.1

* % Relative to local index

Company news